INVO

INVO Bioscience

( )

Page Views : 219294

Analyst Ratings

Strong
Buy

Strong Buy

50%

Buy

50%

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Sector

Healthcare

Industry

Medical Devices

Exchange

Nasdaq

Ticker

INVO

vista's key points

INVO operates within the ~$15-$18 Billion global infertility industry growing ~8-10% annually.
INVO is commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an accessible, inclusive, and affordable treatment for patients diagnosed with infertility.
INVOcell is an FDA cleared patented medical device that is one of only 3 ways today that a couple that is struggling with infertility may choose to use to try to get pregnant and that offers a more economical and natural way to proceed.
INVOcell addresses key industry challenges regarding cost & capacity constraints of in vitro- fertilization (IVF).
INVOcell is positioned to serve a vastly underserved global market as ~+90% of infertile individuals go untreated exposing a significant unmet market opportunity.
INVO is pushing forward with a combined distribution, joint venture/partner model to establish INVO-only clinics (2 open in the US & 1 in Mexico) to accelerate adoption of INVOcell and their business worldwide.
INVO now has distribution agreements in place in within 9 countries in Africa, Asia (China, Taiwan), Europe, & Middle East continues to seek further relationships worldwide.
INVO opened INVOcell dedicated clinics or INVO Centers in Atlanta & Birmingham in 2021 & is seeking to open 1 the San Francisco Bay Area
INVO opened first INVO Center in Mexico Q4/2021.
INVO a "low" or "tight float" with only 12.7M shares issued and outstanding as of Jan 1, 2023.

Click Here To Learn More

Trade Now

vista's key points

INVO operates within the ~$15-$18 Billion global infertility industry growing ~8-10% annually.
INVO is commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an accessible, inclusive, and affordable treatment for patients diagnosed with infertility.
INVOcell is an FDA cleared patented medical device that is one of only 3 ways today that a couple that is struggling with infertility may choose to use to try to get pregnant and that offers a more economical and natural way to proceed.
INVOcell addresses key industry challenges regarding cost & capacity constraints of in vitro- fertilization (IVF).
INVOcell is positioned to serve a vastly underserved global market as ~+90% of infertile individuals go untreated exposing a significant unmet market opportunity.
INVO is pushing forward with a combined distribution, joint venture/partner model to establish INVO-only clinics (2 open in the US & 1 in Mexico) to accelerate adoption of INVOcell and their business worldwide.
INVO now has distribution agreements in place in within 9 countries in Africa, Asia (China, Taiwan), Europe, & Middle East continues to seek further relationships worldwide.
INVO opened INVOcell dedicated clinics or INVO Centers in Atlanta & Birmingham in 2021 & is seeking to open 1 the San Francisco Bay Area
INVO opened first INVO Center in Mexico Q4/2021.
INVO a "low" or "tight float" with only 12.7M shares issued and outstanding as of Jan 1, 2023.

Click Here To Learn More

Sector

Healthcare

Industry

Medical Devices

Exchange

Nasdaq

Ticker

INVO

company profile

INVO Bioscience, Inc. (NASDAQ: INVO) is a commercial-stage fertility company dedicated to expanding the assisted reproductive technology (“ART”) marketplace by making fertility care accessible and inclusive to people around the world. Their flagship product is INVOcell®, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Their primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. This treatment solution is the world’s first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as “IVC”, provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. The IVC procedure can deliver comparable results at a fraction of the cost of traditional in vitro fertilization (“IVF”) and is a significantly more effective treatment than intrauterine insemination (“IUI”). Our commercialization strategy is focused on the opening of dedicated “INVO Centers” offering the INVOcell® and IVC procedure (with three centers in North America now operational), in addition to continuing to sell our technology solution into existing fertility clinics. For more information, please visit www.invobio.com.

vista's view

INVO Bioscience (INVO) is an emerging growth company that owns the INVOcell system, an FDA cleared patented medical device that is one of only 3 ways today that a couple that is struggling with infertility may choose to use to try to get pregnant and that offers a more economical and natural way to proceed. Depending on what statistics that you review today, Industry forecasts suggest that no more than 10% of the estimated 150 million infertile couples worldwide are currently being treated. After further research, this severely underserved market has been created and left unaddressed primarily because of capacity constraints, access to care & the associated cost issues, which the INVOcell system is believed to be in prime position to address.

For many couples struggling with infertility, access to treatment is often unavailable. Financial challenges (i.e. cost of treatment) and limited availability (or capacity) of fertility medical care are two of the main challenges in the ART marketplace that contribute to the large percentage of untreated patients. Religious, social and cultural roadblocks can also prevent hopeful couples from realizing their dream to have a baby with conventional IVF. INVO believes INVOcell can address many of the key challenges in the ART market, particularly patient cost and infrastructure capacity constraints.

The many benefits of the INVO Solution include: 1. Cost: Current U.S.-based clinics offering INVOcell are doing so at approximately half the cost of IVF treatment, due to less drugs often being prescribed for INVOcell, fewer office visits and less laboratory time needed as incubation is occurring inside the body rather than a lab incubator. 2. Enhances Industry Capacity: The INVOcell device eliminates the need for a lab incubator as well as helps reduce the overall need for lab-support resources during the incubation period. We believe this generally supports the ability to lower costs as well as enable a clinic to handle a higher volume of patients. 3. Promotes greater involvement by couples in the treatment and conception. 4. Reduces the risk of errors of wrong embryo transfers since the embryos are never separated from the woman. 5. Creates a more natural and environmentally stable incubation than traditional IVF in the laboratory.

Click Here To Learn More About INVO Bioscience (INVO) & the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®!

Read Less